Endo shares not reflecting value of combined business, says BWS Financial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 18 2025
0mins
Should l Buy ?
Endo's Business Developments: Endo has finalized the sale of its international business and is nearing completion of its merger with Mallinckrodt, which BWS Financial believes will enhance value through synergies.
Stock Valuation and Rating: BWS maintains a Buy rating on Endo shares with a price target of $40, arguing that the current share price does not reflect the potential value post-merger, especially as free cash flow is expected to reduce debt in the first year after the merger.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
